Patrick Daly

Cancer Nursing Today nonprod

Graft-versus-host disease (GVHD) is a serious complication following allogeneic hematopoietic cell transplantation (HCT). Some treatments have shown efficacy for preventing GVHD, including tacrolimus, methotrexate, and antithymocyte globulin (ATG), as well as posttransplant cyclophosphamide (PTCy); however, the optimal treatment has not been established.In a recent study, researchers compared the rate of GVHD-free, relapse-free survival (GRFS) after mismatched unrelated donor (MMUD) HCT with either ATG-based or <a href="https://cancernursingtoday.com/post/characterizing-chronic-gvhd-after-ptcy-transplants">PTCy-based prophylaxis for GVHD</a>. Based on their findings, which were published in Blood Advances, the researchers reported that PTCy-based GVHD prevention yielded superior GRFS and overall survival.<h3>PTCy Appears&nbsp; Superior to ATG for GVHD Prevention</h3>The study included 46 patients who received ATG plus tacrolimus and methotrexate and 82 patients who received PTCy plus mycophenolate mofetil and tacrolimus or sirolimus. Participants received transplants from donors mismatched at 1 or more locus among HLA-A, HLA-B, HLA-C, and HLA-DRB1. The researchers noted that patients in the PTCy group received more bone marrow grafts compared with the ATG group (50% vs 26%; P=.01), and more had more than 1 HLA mismatch (30.5% vs 2.2%; P=.001).According to the report, patients in the PTCy group had a 1-year GRFS rate of 54% (95% CI, 44%-66%), whereas patients in the ATG group had a rate of 16% (95% CI, 8%-31%; P&lt;.001). The rate of overall survival in the PTCy group was 75% (95% CI, 66%-85%) compared with 45% in the ATG group (95% CI, 32%-62%; P&lt;.001), and 1-year nonrelapse mortality was greater in the ATG group (38%; 95% CI, 23%-52%) compared with the PTCy group (16%; 95% CI, 9%-25%; P&lt;.001).&ldquo;The results of the current study indicate that PTCy resulted in improved clinical outcomes after MMUD HCT,&rdquo; the authors summarized. &ldquo;PTCy should be favored as the primary mechanism to prevent GVHD in this setting, in the absence of randomized, prospective clinical trial data.&rdquo;Find More <a href="https://cancernursingtoday.com/page/gvhd">Recent Studies on Graft-Versus-Host Disease</a>

GVHD-Free, Relapse-Free Survival With PTCy Versus ATG After HCT

GVHD

PTCy-based GVHD prophylaxis showed superior GRFS and OS compared with ATG-based prophylaxis in a recent study.

Survival With PTCy Versus ATG After HCT

About Us

Editorial Policy

Authors

Advertising

eNewsletters

Contact Us

Contribute

Calendar of Events

Career Center

Blood Cancers Today

GU Oncology Now

DocWire News

MashupMD

Urban Health Today

Breast Cancer

Colorectal Cancer

GI Cancer

GU Cancer

Gynecologic Cancer Awareness Month

Gyn-Onc

Blood Cancer Awareness Month

Leukemia

Lymphoma

Myeloproliferative Neoplasms

Multiple Myeloma

Myelodysplastic Syndrome

Myelofibrosis

Sickle Cell

Hem/Onc

Professional Development

Patient Voice

Lung Cancer

Skin Cancer

Other Tumor Types

News

Treatment

More

Conferences

Calendar

CARE Award

Best Practices

Expert Interviews

Subscribe